24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2373-8057
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease ; volume:4 ; number:1 ; day:20 ; month:11 ; year:2018 ; pages:1-5 ; date:12.2018
npj Parkinson's Disease ; 4, Heft 1 (20.11.2018), 1-5, 12.2018

Creator
Cruse, Belinda
Morales-Briceno, Hugo
Chang, Florence C F.
Mahant, Neil
Ha, Ainhi D.
Kim, Samuel D.
Wolfe, Nigel
Kwan, Vu
Tsui, David S.
Griffith, Jane M.
Galea, Donna
Fung, Victor S C.
Contributor
SpringerLink (Online service)

DOI
10.1038/s41531-018-0070-4
URN
urn:nbn:de:101:1-2018123021465340766823
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:55 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Cruse, Belinda
  • Morales-Briceno, Hugo
  • Chang, Florence C F.
  • Mahant, Neil
  • Ha, Ainhi D.
  • Kim, Samuel D.
  • Wolfe, Nigel
  • Kwan, Vu
  • Tsui, David S.
  • Griffith, Jane M.
  • Galea, Donna
  • Fung, Victor S C.
  • SpringerLink (Online service)

Other Objects (12)

Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease

Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort

Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease

Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease

Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia

Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia

Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease

Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial

Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort

Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort

Predicting levodopa-induced dyskinesia

Predicting levodopa-induced dyskinesia

Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis

Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis

Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease: long-term results from COSMOS

Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease: long-term results from COSMOS

The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson’s disease

The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson’s disease

Related objects